Clinical Trials Browser

OTHER × Prostatic Neoplasms × Radiation × Clear all

NCT04513717 2026-04-03

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05946213 2026-04-03

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT06244004 2026-03-30

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Phase 2 Recruiting

Prostatic Neoplasms

NCT06171269 2026-03-04

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

Phase NA Recruiting

Prostatic Neoplasms

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT06037863 2026-02-23

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

Phase NA Active not recruiting

Prostatic Neoplasms

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT03861676 2026-02-13

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

Phase EARLY_PHASE1 Recruiting

Prostatic Neoplasms

NCT06625034 2026-02-10

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT07202247 2026-02-04

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Phase 2 Recruiting

Prostatic Neoplasms

NCT06205316 2026-01-20

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Phase 3 Recruiting

Prostatic Neoplasms

NCT03371719 2026-01-14

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04134260 2026-01-14

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

Prostatic Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05805371 2025-11-19

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms

NCT03987386 2025-11-12

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT03889119 2025-09-15

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Phase NA Active not recruiting

Prostatic Neoplasms

NCT05230251 2025-09-12

ROADSTER

Phase 1/2 Completed

Prostatic Neoplasms

NCT03570827 2025-09-03

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Phase 2 Completed

Prostatic Neoplasms

NCT01508390 2025-06-26

Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate

Phase NA Active not recruiting

Prostatic Neoplasms

NCT04249154 2025-06-25

PROMPT

Phase 2 Recruiting

Prostatic Neoplasms

NCT01342367 2025-06-10

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Phase NA Active not recruiting

74 enrolled 12 charts

Prostatic Neoplasms

NCT02184533 2024-05-28

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

Phase 1 Completed

GenitourinaryPlasma cell

Multiple Myeloma, Plasmacytoma, Prostatic Neoplasms

NCT06129851 2023-11-13

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT03649841 2023-10-26

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Phase 2 Terminated

10 enrolled 7 charts

Prostatic Neoplasms

NCT03043807 2023-02-16

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Phase 2 Completed

26 enrolled 8 charts

Prostatic Neoplasms

NCT05717582 2023-02-08

CHAMPION

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT04457245 2023-01-17

PSMA-dRT

Phase 3 Terminated

Prostatic Neoplasms

NCT00860652 2022-11-18

RAVES

Phase NA Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT02064036 2022-10-18

CCRO025

Phase 1 Completed

Prostatic Neoplasms

NCT02716974 2022-08-04

oligo-mets

Phase 2 Completed

26 enrolled 8 charts

Prostatic Neoplasms

NCT00116142 2022-01-11

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Phase 3 Completed

350 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT01833208 2021-08-05

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Phase NA Completed

Prostatic Neoplasms

NCT02229734 2021-06-04

FASTR-2

Phase 2 Completed

Prostatic Neoplasms

NCT04585932 2021-01-20

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Phase 2 Withdrawn

Prostatic Neoplasms

NCT02064582 2020-10-12

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

Phase 2 Completed

7 enrolled 6 charts

Prostatic Neoplasms

NCT01303705 2018-08-29

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT01677845 2017-08-28

Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT01642732 2017-05-30

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Phase 1 Terminated

1 enrolled 2 charts

Neoplasms, Prostatic Neoplasms

NCT01641185 2017-05-04

IPI

Phase 2 Completed

Prostatic Neoplasms

NCT00033605 2016-07-13

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Phase 3 Completed

GastrointestinalGenitourinaryGynecologicSarcoma

Uterine Cervical Neoplasms, Diarrhea, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT00023686 2016-07-06

Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT01041326 2013-07-17

Preoperative Radiation Therapy for High Risk Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT01454037 2012-11-14

Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy

Prostatic Neoplasms